FDA approves migraine pill as preventative treatment
Migraine treatment Nurtec, developed by US firm Biohaven, is now approved for preventative and acute use.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT
The preventative treatment industry for migraines has gained a new player in the form of US-based firm Biohaven, which can now start competing with companies like Lundbeck, Amgen and Eli Lilly following a recent FDA approval.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck backs Trintellix with new data
For subscribers
.jpg&w=384&q=75)
